AstraZeneca shares fall on report of potential China probe fallout
AstraZeneca shares recorded their biggest one-day drop since March 2020 on Tuesday following a report that dozens of senior executives at its China unit could be implicated in the largest insurance fraud case in the country's pharma sector in years.
AstraZeneca last week told investors that its China president, Leon Wang, was “cooperating with an ongoing investigation ...
Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...
China's investigation of AstraZeneca's top executive in the country is raising questions about the company's tactics there.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback